Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Kojic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 5/20 | 0.92 |
| ▸ | DAO | P14920 | 5/20 | 0.92 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kojic Acid SCHEMBL5011817 | 0.96 | TYR (1.00) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL36895 | 0.96 | TYR (1.00) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28808848 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28650749 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28491069 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL12538255 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL30518398 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL9780977 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL6786872 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 | |
| Kojic Acid SCHEMBL28654757 | 0.94 | TYR (0.96) | TYRDAOKDM4EIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879243-B2 | Culture medium for cell growth and transfection | LIFETECHNOLOGIES CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140057335-A1 | CULTURE MEDIUM FOR CELL GROWTH AND TRANSFECTION | Life Technologies Corporation (US) | 2014-02-27 | — | — | US | disclosed |
| EP-1385933-B1 | CULTURE MEDIUM FOR CELL GROWTH AND TRANSFECTION | LIFE TECHNOLOGIES CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2351827-A1 | Culture medium for cell growth and transfection | Life Technologies Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183375-A1 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS | Life Technologies Corporation (US) | 2011-07-28 | — | — | US | disclosed |
| US-20080286868-A1 | METAL BINDING COMPOUNDS AND THEIR USE IN CELL CULTURE MEDIUM COMPOSITIONS | INVITROGEN CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| US-20070254358-A1 | Culture medium for cell growth and transfection | INVITROGEN CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| US-6767741-B1 | THE COMPOSITIONS OBVIATE THE NEED FOR NATURALLY DERIVED METAL-BINDING PROTEINS, SUCH AS TRANSFERRIN AND CERULOPLASMIN, WHICH MAY CONTAIN BLOOD-BORNE PATHOGENS | INVITROGEN CORPORATION | 2004-07-27 | — | — | US | disclosed |